Syros Pharmaceuticals Gave Notice To Qiagen Manchester Limited Of Its Election To Terminate The Master Collaboration Agreement Dated March 7, 2022
Syros Pharmaceuticals Gave Notice To Qiagen Manchester Limited Of Its Election To Terminate The Master Collaboration Agreement Dated March 7, 2022
On November 13, 2024, Syros Pharmaceuticals, Inc. (the "Company") gave notice to QIAGEN Manchester Limited ("QIAGEN") of its election to terminate the Master Collaboration Agreement dated March 7, 2022 (the "Agreement") relating to the development and commercialization of an assay as a companion diagnostic test for use with tamibarotene as a result of the failure of the Company's SELECT-MDS-1 Phase3 trial evaluating tamibarotene to meet its primary endpoint of complete response rate, which was previously disclosed on the Company's Current Report on Form 8-Kfiled with the U.S. Securities and Exchange Commission (the "SEC") on November 13, 2024. The termination will be effective 90 days following such notice.
2024年11月13日，锡罗斯制药公司（以下简称 “公司”）通知QIAGEN 曼彻斯特有限公司（“QIAGEN”），由于该公司的SELECT-MDS-1 Phase3阶段试验评估失败，该公司选择终止2022年3月7日与他米巴罗汀一起使用的伴随诊断测试方法的开发和商业化的主合作协议（“协议”）ibarotene将达到其完整回复率的主要终点，该终点此前已在公司提交的8-K表最新报告中披露将于 2024 年 11 月 13 日与美国证券交易委员会（“SEC”）签约。终止将在发出此类通知后的 90 天内生效。
